A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy
Author:
Funder
Ministry of Science and Technology, Taiwan
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference33 articles.
1. Global cancer statistics;Jemal;CA Cancer J. Clin,2011
2. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival;Llovet;Hepatology,2003
3. Systematic review: evidence-based management of hepatocellular carcinoma–an updated analysis of randomized controlled trials;Lopez;Aliment. Pharmacol. Ther,2006
4. Sorafenib in advanced hepatocellular carcinoma;Llovet;N. Engl. J. Med,2008
5. HCC therapies–lessons learned;Worns;Nat. Rev. Gastroenterol. Hepatol,2014
Cited by 29 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Impacts of small-molecule STAT3 inhibitor SC-43 on toxicity, global proteomics and metabolomics of HepG2 cells;Journal of Pharmaceutical and Biomedical Analysis;2024-05
2. Treating liver cancer through arginine depletion;Drug Discovery Today;2024-04
3. Coordinative Activities of STAT3 Inhibitor BP-1-102 and Sorafenib Against Proliferation, Angiogenesis and EMT in Hepatocellular Carcinoma;2023-09-22
4. Regorafenib induces damage-associated molecular patterns, cancer cell death and immune modulatory effects in a murine triple negative breast cancer model;Experimental Cell Research;2023-08
5. Novel thieno[2,3-b]quinoline-procaine hybrid molecules: A new class of allosteric SHP-1 activators evolved from PTP1B inhibitors;Chinese Chemical Letters;2022-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3